CytoDyn Inc (OTCQB:CYDY) has shared strong preliminary results from its Phase 1b/2 trials and compassionate use study of its flagship drug candidate leronlimab in 30 metastatic triple-negative breast cancer (mTNBC) patients. The leronlimab trial is being carried out in combination with carboplatin for the treatment of
Full Story >>
Vote
+21